Veeva Revenue Jumps 17% in Fiscal Q2

Veeva Systems (NYSE:VEEV) delivered a strong Q2 FY2026, with GAAP revenue increasing 17% year-over-year to $789.1 million and non-GAAP EPS growing 22.8% to $1.99, both exceeding analyst expectations. The company expanded its non-GAAP operating margin to 44.7% and significantly boosted free cash flow. Key operational highlights include securing over 100 Vault CRM customers, resolving its IQVIA dispute with a new global partnership, and advancing AI and Data Cloud initiatives with first AI agent tools slated for release in December 2025. Despite a one-time litigation charge impacting G&A expenses, Veeva provided an optimistic full-year outlook, signaling continued double-digit growth and strategic investment in its specialized cloud solutions and AI capabilities for the life sciences industry.

Analysis

Veeva Systems reported a strong fiscal second quarter for 2026, outperforming expectations on both revenue and profitability. GAAP revenue grew 17% year-over-year to $789.1 million, surpassing analyst estimates, driven by robust performance in its subscription services, particularly the R&D Solutions segment which saw a 21.5% revenue increase. The company demonstrated significant operating leverage, with the non-GAAP operating margin expanding 3.3 percentage points to 44.7% and non-GAAP EPS growing 22.8% to $1.99. This financial strength is further evidenced by a 145.8% surge in non-GAAP free cash flow to $225.4 million. Strategically, Veeva achieved several key milestones that strengthen its market position. The resolution of the long-standing legal dispute with IQVIA and the subsequent formation of a global partnership removes a major overhang and creates potential for new integrated sales opportunities. Operationally, the company is executing well on its product roadmap, having now deployed its next-generation Vault CRM to over 100 customers and advancing a clear multi-year AI strategy with the first AI agent tools slated for a December 2025 release. A point of concern is the sharp 56% rise in GAAP G&A expenses, although this was primarily due to a one-time $30.6 million litigation charge; however, the underlying 25% growth in this expense line warrants monitoring. The forward guidance for the full year, projecting revenue near $3.14 billion and non-GAAP EPS of approximately $7.78, signals management's confidence in maintaining double-digit growth.

Key Decisions for Investors

• Given the strong top-line beat, margin expansion, and robust forward guidance, investors may view the results as a confirmation of Veeva's strong execution and market leadership in the life sciences cloud sector.
• The resolution of the IQVIA litigation and establishment of a new partnership significantly de-risks the stock and introduces a potential catalyst for future revenue synergies that may not be fully priced in.
• Investors should monitor the company's progress on its AI product roadmap, as the successful launch of AI agents in late 2025 and other data products in 2026-2027 is critical for sustaining long-term growth and its competitive edge against rivals like Salesforce.
• While the one-time litigation charge explains the spike in G&A costs, the underlying 25% growth in this expense line should be watched closely in subsequent quarters to ensure cost discipline is maintained and does not erode future profitability gains.